Molecular Repair of Diabetic Mesenchymal Stem Cells (dMSC) for Peripheral Arterial Disease

糖尿病和外周动脉疾病(PAD)对我国退伍军人的影响不成比例。糖尿病患者 患者的组织中的侧枝循环和再生能力有限。患有糖尿病的患者 外周动脉疾病有严重的缺血性并发症，并面临重大截肢的严重风险。 通过外科血管重建术逆转组织缺血可以防止截肢，但许多糖尿病患者 外周动脉疾病不能通过外科血管重建术完全治愈。基于再生细胞的 治疗可以在重建或再生腿部血管供应方面向前迈出完整的一步 防止截肢。我们在糖尿病间充质干细胞中发现了一种独特的细胞内信号缺陷 可以被有利地修改以改善这些细胞的细胞。这项建议将考验其有效性、耐用性 然后利用相关的体外和体内实验研究了这种方法在糖尿病条件下的作用机制。 模特们。积极的结果将被用来将这些方法转化为患有糖尿病和PAD的退伍军人。

Diabetes and peripheral arterial disease (PAD) disproportionately affect our nation's Veterans. Diabetic patients have limited collateralization and regenerative capacity in their tissues. Diabetic patients with peripheral arterial disease have severe ischemic complications and are at grave risk of major amputation. Reversing tissue ischemia by surgical revascularization prevents amputations, but many patients with diabetes and peripheral arterial disease are not fully treatable by surgical revascularization. Regenerative cell-based therapies may enable a full step forward in re-establishing or regenerating the vascular supply of the leg to prevent amputations. We have identified a unique intracellular signaling defect in diabetic mesenchymal stem cells that can be favorably modified to improve these cells. This proposal will test the effectiveness, durability and then mechanism by which this approach works under diabetic conditions using relevant in vitro and in vivo models. Positive results will be used to translate these methods to Veterans with diabetes and PAD.